LITERATURE CITED

Alam, M. T., H. Bora, P. K. Bharti, M. A. Saifi, M. K. Das, V. Dev, A. Kumar, N. Singh, A. P. Dash, B. Das, S. Wajihullah and D. Yagya. 2007. Similar trends of pyrimethamine resistance-associated mutations in *Plasmodium vivax and P. falciparum*. **Antimicrob. Agents. Chemother.** 51(3): 857-863.

Alker, A. P., V. Mwapasa and R. Meshnick. 2004. Rapid Real-time PCR Genotyping of Mutations Associated with Sulfadoxine-Pyrimethamine Resistance in *Plasmodium falciparum*. **Antimicrob. Agents. Chemother.** 48(8): 2924-2929.

Avery, M. A., K. M. Muraleedharan, P. V. Desai, A. K. Bandyopadhyaya, M. M. Furtado and B. L. Tekwani. 2003. Structure-activity relationships of the antimalarial agent artemisinin. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria. **J. Med. Chem**. 46(20): 4244-4258.

Avery, M. A., M. Alvim-Gaston, C. R. Rodrigues, E. J. Barreiro, F. E. Cohen, Y. A. Sabnis and J. R. Woolfrey. 2002. Structure-activity relationships of the antimalarial agent artemisinin. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies. **J. Med. Chem.** 45(2): 292-303.

Basco, L. K., P. E. Pecoulas, C. M. Wilson, J. L. Bras and A. Mazabraud. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in *Plasmodium falciparum*. **Mol. Biochem. Parasitol**. 69: 135-138.

Botelho, A. 1971. Chemotherapy of malaria. Short historical review. **Anais da Escola Nacional de Saude Publicaede Medicina Tropical, Lisbon**. 5(1/2): 99-114.

Boys, S. F. and F. Bernardi. 1970. The calculations of small molecular interaction by the difference of separate total energies some procedures with reduced error. **Mol. Phys**. 19: 553-566.

Brobey, R. K. B., G. Sano, F. Itoh, K. Aso, M. Kimura, T. Mitamura and T. Horii. 1996. Recombinant *Plasmodium falciparum* dihydrofolate reductase-based in vitro screen for antifolate antimalarials. **Mol. Biochem. Parasitol**. 81: 225-237.

Brown, R.D. and Y.C. Martin. 1997. The information content of 2D and 3D structural descriptors relevant to ligand-receptor binding. **J. Chem. Inf. Comput. Sci.** 37: 1-9.

Bush, B. L. and R. B. Jr. Nachbar. 1993. Sample-distance Partial Least Squares: PLS optimized for many variables, with application to CoMFA. **J. Comput. Aided Mol. Des.** 7: 587-619.

Case, D. A., T. A. Darden, III. T. E. Cheatham, C. L. Simmerling, J. Wang, R. E. Duke, R. Luo, K. M. Merz, D. A. Pearlman, M. Crowley, R. C. Walker, W. Zhang, B. Wang, S. Hayik, A. Roitberg, G. Seabra, K. F. Wong, F. Paesani, X. Wu, S. Brozell, V. Tsui, H. Gohlke, L. Yang, C. Tan, J. Mongan, V. Hornak, G. Cui, P. Beroza, D. H. Mathews, C. Schafmeister, W. S. Ross and P. A. Kollman. 2006. **AMBER9.0**.

Collins W. E., and G. M. Jeffery. 2007. *Plasmodium malariae*: parasite and disease. **Clin. Microbiol. Rev**. 20(4): 579-592.

Cramer, R. D. III, D. E. Patterson and J. D. Bunce. 1988. Comparative Molecular Field Analysis CoMFA: 1. Effect of shape on binding of steroids to carrier proteins. **J. Am. Chem. Soc**. 110: 5959-5967.

Cramer, R. D. III, D. E. Patterson and J. D. Bunce. 1989. Recent advances in comparative molecular field analysis (CoMFA). **Prog. Clin. Biol. Res**. 291: 161-165.

Cheng, F., J. Shen, X. Luo, W. Zhu, J. Gu, R. Ji, H. Jiang and K. Chen. 2002. Molecular docking and 3D-QSAR studies on the possible antimalarial mechanism of artemisinin analogues. **Bioorg. Med. Chem**. 10: 2883-2891.

Chusacultanachai, S., P. Thiensathit, B. Tarnchompoo, W. Sirawaraporn and Y. Yuthavong. 2002. Novel antifolate resistant mutations of *Plasmodium falciparum* dihydrofolate reductase selected in Escherichia coli. **Mol. Biochem. Parasitol**. 120: 61-72.

Cho, S. J. and A. Tropsha. 1995. Cross-Validated R2-Guided Region Selection for Comparative Molecular Field Analysis: A Simple Method To Achieve Consistent Results**. J. Med. Chem**. 38: 1060-1066.

Clark, D.E. and D.R. Westhead. 1996. Evolutionary algorithms in computer-aided molecular design. **J. Comput. Aided Mol. Des**. 4: 337-358.

Clark, M. and R. D. III. Cramer. 1993. The Probability of Chance Correlation Using Partial Least Squares (PLS). **Quant. Struct.-Act. Relat**. 12(2): 137-145.

Cody, V. and C. H. Schwalbe. 2006. Structural characteristics of antifolate dihydrofolate reductase enzyme interactions. Crystallog. Rev. 12 (4), 301-333.

Cornell, W. D., P. Cieplak, C. I. Bayly and P. A. Kollman. 1993. Application of RESP Charges to Calculate Conformational Energies, Hydrogen-bond Energies, and Free-energies of Solvation, **J. Am. Chem. Soc**. 115, 9620–9631.

Cui, Z., L. Zhang and R. Li. 1997. Studies on synthesis of lipophilic antifolate 2,4-diamino-5-methyl-6-(substituted benzylamino) quinazoline compounds with methods of 2D- and 3D-QSAR. **J. Chin. Pharm. Sci**. 6(2): 113-114.

Cui, Z., W. Zhao and R. Li. 1999. 3D-QSAR study on lipophilic antifolates quinazolines. **Prog. Nat. Sci**. 9(7): 516-519.

Cummins, P. L., K. Ramnarayan, U. C. Singh and J. E. Gready. 1991. Molecular dynamics/free energy perturbation study on the relative affinities of the binding of reduced and oxidized NADP to dihydrofolate reductase. **J. Am. Chem. Soc**. 113(22): 8247-8256

Czaplinski, K-H., W. Hansel, M. Wiese and JK. Seydel. 1995. New benzylpyrimidines: inhibition of DHFR from various species. QSAR, CoMFA and PC analysis. **Eur. J. Med. Chem**. 30: 779-787.

Dapprich, S., I. Komaromi, K. S. Byun, K. Morokuma and M. J. Frisch. 1999. A new ONIOM implementation in Gaussian98. partI. The calculation of energies, gradients, vibrational frequencies and electric field derivatives. **J. Mol. Struct. (Theochem)** 461-462: 1-21.

Dasgupta, T. and K. S. Anderson. 2008. Probing the Role of Parasite-Specific, Distant Structural Regions on Communication and Catalysis in the Bifunctional Thymidylate Synthase- Dihydrofolate Reductase from *Plasmodium falciparum*. **Biochemistry** 47(5): 1336-1345.

Delfino, R. T., O. A. Santos-Filho and J. D. Figueroa-Villar. 2002. Molecular modeling of wild-type and antifolate resistant mutant *Plasmodium falciparum* DHFR. **Biophys. Chem**. 98: 287-300.

Delfino, R. T., O. A. Santos-Filho and J. D. Figueroa-Villar. 2002. Type 2 antifolates in the chemotherapy of *falciparum* malaria. **J. Braz. Chem. Soc**. 13: 727-741.

Edstein, M. D., A. E. T. Yeo, G. D. Shanks and K. H. Rieckmann. 1997. Ex vivo antimalarial activity of proguanil combined with dapsone against cycloguanil-resistant *Plasmodium falciparum* isolates. **Acta Tropica**. 66: 127-135.

Fidock, D. A., T. Nomura and T. E. Wellems. 1998. Cycloguanil and its parent compound proguanil demonstrate distinct activities against *Plasmodium falciparum* malaria parasites transformed with human dihydrofolate reductase. **Mol. Pharmacol**. 54(6): 1140-1147.

Fogel, G. B., M. Cheung, E. Pittman and D. Hecht. 2008. Modeling the inhibition of quadruple mutant *Plasmodium falciparum* dihydrofolate reductase by pyrimethamine derivatives. **J. Comput. Aided. Mol. Des**. 22: 29–38.

Frisch, M. J., G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. A. Jr. Montgomery, T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez and J. A. Pople. 2003. **Gaussian 03**, revision B.05;Gaussian, Inc.: Pittsburgh.

Gatton, M. L. and Q. Cheng. 2006. *Plasmodium falciparum* infection dynamics and transmission potential following treatment with sulfadoxine- pyrimethamine. **J. Antimicrob. Chemoth**. 58(1): 47-51.

Golbraikh, A. and A. Tropsha. 2002. Beware of q2!. **J. Mol. Graph. Mod**. 20: 269-276.

Golbraikh, A., P. Bernard and J. R. Chretien. 2000. Validation of protein-based alignment in 3D quantitative structure-activity relationship with CoMFA models. **Eur. J. Med. Chem**. 35: 123-136.

Gregson, A. and C.V. Plowe. 2005. Mechanisms of Resistance of Malaria Parasites to Antifolates. **Pharmacol. Rev**. 57, 117-145.

Hansch, C. and A. Leo. 1995. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. *American Chemical Society, Washington, DC.*

Hansch, C and T. Fujita. 1964. A method for the correlation of biological activity and chemical structure. **J. Am. Chem. Soc**. 86: 161-1626.

Hannongbua, S., K. Nivesanond, L. Lawtrakul, P. Pungpo and P. Wolschann. 2001. 3D-Quantitative Structure-Activity Relationships of HEPT Derivatives as HIV-1 Reverse Transcriptase Inhibitors, Based on Ab Initio Calculations. **J. Chem. Inf. Comput. Sci.** 41: 848-855.

Haraldson, C. A., J. M. Karle, S. G. Freeman, R. K. Duvadie and M. A. Avery. 1997. The synthesis of 8,8-disubstituted tricyclic analogs of artemisinin. **Bioorgan. Med. Chem. Lett.** 7(18): 2357-2362.

Hastings, I. M. and M. J. Donnelly. 2005. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. **Drug Resist. Updat.** 8: 43-50.

Hekmat-Nejad, M. and P. K. Rathod. 1997. *Plasmodium falciparum*: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. **Exp. Parasitol.** 87: 222-228.

Jung, M. and H. Kim. 2001. CoMFA of artemisinin derivatives: effect of location and size of lattice. **Bioorg. Med. Chem. Lett**. 11: 2041-2044.

Kamchonwongpaisan, S., R. Quarrell, N. Charoensetakul, R. Ponsinet, T. Vilaivan, J. Vanichtanankul, B. Tarnchompoo, W. Sirawaraporn, G. Lowe and Y. Yuthavong. 2004. Inhibitors of multiple mutants of *Plasmodium falciparum* dihydrofolate reductase and their antimalarial activities. **J. Med. Chem**. 47: 673-680.

Kim, K. H., G. Greco and E. Novellino. 1998. A Critical Review of Recent CoMFA Applications. **Perspect. Drug Discov. Des.** 257–315.

Kokpol, S.K., S.V. Hannongbua, N. Thongrit, S. Polman, B.M. Rode and M.G. Schwendinger. 1988. Analysis of structure-activity relation for primaquine antimatlarial drugs by a quantum pharmacological approach. **Anal. Sci**. 4: 565-568.

Kubinyi, H. 1993. QSAR: Hansch Analysis and Related Approaches; *VCH: Weinheim*.

Kubinyi, H., G. Flokers and Y. C. Martin. 1998. 3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarlity. **Perspect. Drug Discov. Des**. 3-398.

Kuno, M., R. Hongkrengkai and S. Hannongbua. 2006. ONIOM-BSSE scheme for H--¶ system and applications on HIV-1 reverse transcriptase. **Chem. Phys. Lett**. 424: 172-177.

Kuno, M., S. Hannongbua and K. Morokuma. 2003. Theoretical investigation on nevirapine and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method. **Chem. Phys. Lett**. 380: 456–463.

Krudsood, S., S. N. Patel, N. Tangpukdee, W. Thanachartwet, W. Leowattana, K. Pornpininworakij, A. K. Boggild, S. Looareesuwan and K. C. Kain. 2007. Efficacy of atovaquone- proguanil for treatment of acute multidrug-resistant *Plasmosium falciparum* malaria in Thailand. **Am. J. Trop. Med. Hyg.** 76(4): 655-658.

Leartsakulpanich, U., M. Imwong, S. Pukrittayakamee, N. J. White, G. Snounou, W. Sirawaraporn and Y. Yuthavong. 2002. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in *Plasmodium vivax*. **Mol. Biochem. Parasitol**.119: 63-73.

Liu, M., P. Wilairat, S. L. Croft, A. L-C. Tan and M-L. Go. 2003. Structure-activity relationships of antileishmanial and antimalarial chalcones. **Bioorgan. Med. Chem.** 11(13): 2729-2738.

Marbiah**,** N. T., E. Petersen, K. David, E. Magbity, J. Lines and D. J. Bradley. 1998. A Controlled Trial of Lambda-cyhalothrin-impregnated Bed Nets and/or Dapsone/Pyrimethamine for Malaria Control in Sierra Leone. **Am. J. Trop. Med. Hyg**. 58(1): 1-6.

Marshell, G. R. and R. D. III, Cramer. 1988. Three-dimensional structure-activity relationships. **Trends Pharmacol. Sci.** 9(8): 285-289.

Martin, S. 2007. Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics and Drugs in Clinical Development. **ChemMedChem**, 2(7): 944-986.

Matsika-Claquin, M. D., D. Menard, A. L. Fontanet, A. Ngwhotue, J. Sarda and A. Talarmin. 2006. Efficacy of chloroquine- proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case-control study. **Trop. Med. Hyg.** 100(4): 381-386.

Matsubara, T., M. Dupuis and M. Aida. 2007. The ONIOM molecular dynamics method for biochemical applications: Cytidine deaminase. **Chem. Phys. Lett.** 437: 138–142.

Mattioni, B. E. and P. C. Jurs. 2003. Prediction of dihydrofolate reductase inhibition and selectivity using computational neural network and linear discriminant analysis**. J. Mol. Graph. Model.** 21: 391-419.

Militello, K., M. Dodge, L. Bethke and D. F. Wirth. 2004. Identification of regulatory elements in the *Plasmodium falciparum* genome. **Mol. Biochem. Parasitol**. 134: 75-88.

Meshnick, S. R. and M. J. Dobson. 2001. The history of antimalarial drugs. **Antimalarial Chemoth.** 15-25.

Morokuma, K., Q. Wang and T. Vreven. 2006. Performance Evaluation of the Three-Layer ONIOM Method: Case Study for a Zwitterionic Peptide. **J. Chem. Theory Comput.** 2(5): 1317-1324.

Nakato, H., R. Vivancos and P. R. Hunter. 2007. A systematic review and meta-analysis of the effectiveness and safety of atovaquone- proguanil (Malarone) for chemoprophylaxis against malaria. **J. Antimicrob. Chemoth.** 60(5): 929-936.

Nilsson, J., S. De Jong and A. K. Smilde. 1997. Multilinear PLS analysis application to 3D QSAR data set. **J. Chemometrics**. 11: 511-524.

Nosten, F., R. McGready, U. Alessandro, A. Bonell, F. Verhoeff, C. Menendez, M. Clara, T. Mutabingwa and B. Brabin. 2006. Antimalarial drugs in pregnancy: a review. **Curr. Drug Safety**. 1(1): 1-15.

Nunrium, P., M. Kuno, S. Saen-oon and S. Hannongbua. 2005. Particular interaction between efavirenz and the HIV-1 reverse transcriptase binding site as explained by the ONIOM2 method. **Chem. Phys. Lett.** 405: 198–202.

Nzila, A. 2006. Inhibitors of De-novo Folate Enzymes in Plasmodium falciparum. **Drug Discov. Today**. 11(19-20), 936-944.

Nzila, A. 2006. The Past, Present and Future of Antifolates in the Treatment of *Plasmodium falciparum* Infection. **J. Antimicrob. Chemother**. 57, 1043-1054.

Olliaro, P. L. and Y. Yuthavong. 1999. An overview of chemotherapeutic targets for antimalarial drug discovery. **Pharmacol. Ther**. 81: 91-110.

Onefelt, A., S. Hellberg and W. Svante. 1986. Relationships between induction of anesthesia and mitotic spindle disturbances studied by means of principal component analysis. **Mutat. Res. Lett.** 174(2), 109-13.

Parenti, M. D., S. Pacchioni, A. M. Ferrari, and G. Rastelli. 2004. Three-Dimensional Quantitative Structure-Activity Relationship Analysis of a Set of *Plasmodium falciparum* Dihydrofolate Reductase Inhibitors Using a Pharmacophore Generation Approach. **J. Med. Chem**. 47: 4258-4267.

Peterson, D. S., W. K. Milhous and T. E. Wellems. 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in *Plasmodium falciparum* malaria. **Proc. Natl. Acad. Sci. U.S.A**. 87: 3018-3022.

Polhemus, M. E., S. Remich, B. Ogutu, J. Waitumbi, M. Lievens, W. R. Ballou and D. G. Jr. Heppner. 2008. Malaria treatment with atovaquone- proguanil in malaria -immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria. **Antimicrob. Agents Chemoth**. 52(4): 1493-1495.

Prapunwattana, P., W. Sirawaraporn, Y. Yuthavong and D. V. Santi. 1996. Chemical synthesis of the *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase gene. **Mol. Biochem. Parasitol**. 83: 93-106.

Rastelli, G., S. Sirawaraporn, P. Sompornpisut, T. Vilaivan, S. Kamchonwongpaisan, R. Quarrell, G. Lowe, Y. Thebtaranonth and Y. Yuthavong. 2000. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with *Plasmodium falciparum* dihydrofolate reductase: structural basis of antifolate resistance. **Bioorg. Med. Chem**. 8: 1117-1128.

Redl, G., R. D. III. Cramer and C. E. Berkoff. 1974. Quantitative drug design. **Chem. Soc. Rev.** 3(3): 273-292.

Saadat, F., M. R. Khorramizadeh and A. Mirshafiey. 2005. Chemoprevention by pyrimethamine. **Immunopharm. Immunot.** 27(2): 233-240.

Saen-oon, S., M. Kuno and S. Hannongbua. 2005. Binding Energy Analysis for Wild-type and Y181C Mutant HIV-1 RT/8-Cl TIBO Complex Structures: Quantum Chemical Calculations Based on the ONIOM Method. **PROTEINS: Structure, Function, and Bioinformatics**. 61: 859–869.

Saen-oon, S., O. Aruksakunwong, K. Wittayanarakul, P. Sompornpisut and S. Hannongbua. 2007. Insight into Analysis of Interactions of Saquinavir with HIV-1 Protease in Comparison between the Wild-type and G48V and G48V/L90M Mutants Based on QM and QM/MM Calculations. **J. Mol. Graph. Model**. 26: 720–727.

Santos-Filho, O. A., R. K. Mishra and A. J. Hopfinger. 2001. Free energy force field (FEFF) 3D-QSAR analysis of a set of *Plasmodium falciparum* dihydrofolate reductase inhibitors. **J. Comput. Aided Mol. Des.** 15: 787–810.

Sao, S. S. and M. Karplus. 2001. Evaluation of designed ligands by a multiple screening method: Application to glycogen phosphorylase inhibitors constructed with a variety of approaches. **J. Comput. Aided Mol. Des.** 15: 613-647.

Schlitzer, M. 2007. Malaria chemotherapeutics. Part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. **ChemMedChem.** 2(7): 944-986.

Sirawaraporn, W., T. Sathitkul, R. Sirawaraporn, Y. Yuthavong and D.V. Santi. 1997. Antifolate-resistant mutants of *plasmodium falciparum* dihydrofolate reductase. **Proc. Natl. Acad. Sci**. 94: 1124-1129.

Sirawaraporn, S., R. Sirawaraporn, S. Yongkiettrakul, A. Anuwatwora, G. Rastelli, S. Kamchonwongpaisan and Y. Yuthavong. 2002. Mutational analysis of *Plasmodium falciparum* dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. **Mol. Biochem. Parasitol**. 39: 127-34.

Sirawaraporn, W., S. Yongkiettrakul, R. Sirawaraporn, Y. Yuthavong and D. V. Santi. 1997. *Plasmodium falciparum*: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. **Exp. Parasitol.** 87: 245-252.

Sirichaiwat, C., C. Intaraudom, S. Kamchonwongpaisan, J. Vanichtanankul, Y. Thebtaranonth and Y. Yuthavong. 2004. Target guided synthesis of benzyl-2,4-diaminopyrimidines: their antimalarial activities and affinities to wild type and mutant dihydrofolate reductases from *plasmodium falciparum*. **J. Med. Chem**. 47: 345-354.

Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint and S. I. Hay. 2005. Estimating Clinical Episodes of Malaria. **Nature**. 434: 214-217.

Sowunmi, A., B. A. Fateye, A. A. Adedeji, G. O. Gbotosho, T. C. Happi, A. E. Bamgboye, O. M. Bolaji and A. M. J. Oduola. 2006. Predictors of the Failure of Treatment with Pyrimethamine-sulfadoxine in Children with Uncomplicated Falciparum Malaria. **Acta Trop**. 98: 6-14.

Svante, W. and M. Sjoestroem. 1986. Linear free energy relationships. Local empirical rules - or fundamental laws of chemistry. A reply to Kamlet and Taft. **Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry.** B40(4): 270-7.

SYBYL Molecular Modelling Softwares, Version 7.0, Tripos Associates, Inc., St. Louis, MO, 63144, USA, 1998.

Tonmunphean, S., V. Parasuk and S. Kokpol. 2000. QSAR study of antimalarial activities and artemisinin-heme binding properties obtained from docking calculations. **Quant. Struct. -Act. Relat**. 19: 475-483.

Tonmunphean, S., S. Kokpol, V. Parasuk, P. Wolschann, R. H. Winger, K. R. Liedl and B. M. Rode. 1998. Comparative molecular field analysis of artemisinin derivatives: ab initio versus semiempirical optimized structures. **J. Comput. Aided Mol. Des.** 12(4): 397-409.

Tschumpera, G. S. and K. Morokuma. 2002. Gauging the applicability of ONIOM (MO/MO) methods to weak chemical interactions in large systems: hydrogen bonding in alcohol dimers. **J. Mol. Struct. (Theochem)** 592: 137–147.

Uhlemann, A. C., Y. Yuthavong and D. A. Fidock. 2005. Mechanisms of Antimalarial Drug Action and Resistance. **Mol. Arch. Malaria**. 429-461.

Verloop, A., W. Hoogenstraaten and J. Tipfer. 1976. Development and application of new steric substituent parameters. **Drug Design.** 7: 165-207.

Vilaivan, T., N. Saesaengseerung, D. Jarprung, S. Kamchonwongpaisan, W. Sirawaraporn and Y. Yuthavong. 2003. Synthesis of solution-phase combinatorial library of 4,6-diamino-1,2-dihydro-1,3,5-triazine and identification of new leads against A16V + S108T mutant dihydrofolate reductase of *Plasmodium falciparum*. **Bioorg. Med. Chem**. 11: 217-224.

Vreven, T. and K. Morokuma. 1999. The accurate calculation and prediction of the bond dissociation energies in a series of hydrocarbons using the IMOMO (integrated molecular orbital + molecular orbital) methods. **J. Chem. Phys**. 111(19): 8799-8803.

Vreven, T. and K. Morokuma. 2000. On the application of the IMOMO (integrated molecular orbital + molecular orbital) method. **J. Com. Chem.** 21(16): 1419-1432.

Vreven, T. and K. Morokuma. 2006. Hybrid methods: ONIOM(QM:MM) and QM/MM. **Annu. Rep. Com. Chem.** 2: 35-51.

Vreven, T., K. S. Byun, I. Komaromi, S. Dapprich, J. A. Jr. Montgomery, K. Morokuma and M. J. Frisch. 2006. Combining Quantum Mechanics Methods with Molecular Mechanics Methods in ONIOM. **J. Chem. Theory Comput.** 2(3): 815-826.

Warhurst, D. C. 2002. Resistance to antifolates in *Plasmodium falciparum*, the causative agent of tropical malaria. **Sci. Prog.** 85: 89-111.

Walliker, D., P. Hunt and H. Babiker. 2005. Fitness of drug-resistant malaria parasites. **Acta Trop**. 94: 251-259.

Wattanarangsan, J., S. Chusacultanachai, J. Yuvaniyama, S. Kamchonwongpaisan and Y. Yuthavong. 2003. Effect of N-terminal truncation of *Plasmodium falciparum* dihydrofolate reductase on dihydrofolate reductase and thymidylate synthase activity. **Mol. Biochem. Parasitol**. 126: 97-102.

Winter, G., Q. Chen and M. Wahlgren. 2004. Meeting report: the molecular background of severe and complicated malaria. **Mol. Biochem. Parasitol**. 134: 37-41.

Yeo, A. E. T., M. D. Edstein and K. H. Rieckmann. 1997. Antimalarial activity of the triple combination of proguanil, atovaquone and dapsone. **Acta Trop**. 67(3): 207-214.

Yuthavong, Y. 2002. Basic for antifolate action and resistance in malaria. **Microbes Infect**. 4: 175-182.

Yuthavong, Y., J. Yuvaniyama, P. Chitnumsub, J. Vanichtanankul, S. Chusacultanachai, B. Tarnchompoo, T. Vilaivan and S. Kamchonwongpaisan. 2005. Malarial (*Plasmodium falciparum*) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. **Parasitol.** 130: 249-259.

Yuthavong, Y., S. Kamchonwongpaisan, U. Leartsakulpanich and P. Chitnumsub. 2006. Folate Metabolism as a Source of Molecular Targets for Antimalarials. **Future Microb**. 1(1): 113-125.

Yuthavong, Y., T. Vilaivan, N. Chareonsethakul, S. Kamchonwongpaisan, W. Sirawaraporn, R. Quarrell and G. Lowe. 2000. Development of a lead inhibitor for the A16V+S108N mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of *plasmodium falciparum*. **J. Med. Chem**. 43: 2738-2744.

Yuvaniyama, J., P. Chitnumsub, S. Kamchonwongpaisan, J. Vanichtanankul, S. Sirawaraporn, P. Taylor, M. D. Walkinshaw and Y. Yuthavong. 2003. Insights into antifolate resistance from malarial DHFR-TS structures. **Nat**. **Struct. Biol**. 10: 357-365.

Zongo, I., G. Dorsey, N. Rouamba, C. Dokomajilar, M. Lankoande, J-B. Ouedraogo and P. J. Rosenthal. 2005. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated *falciparum* malaria: a randomized controlled trial from Burkina Faso. **Am. J. Trop. Med. Hyg.** 73(5): 826-832.